Mills, Matthew N.
Potluri, Thrisha K.
Kawahara, Yuki
Fahey, Matthew
Figura, Nicholas B.
Soyano, Aixa E.
Washington, Iman R.
Diaz, Roberto
Oliver, Daniel E.
Yu, Hsiang-Hsuan Michael
Etame, Arnold B.
Vogelbaum, Michael A.
Czerniecki, Brian J.
Arrington, John A.
Sahebjam, Solmaz
Forsyth, Peter A.
Soliman, Hatem H.
Han, Hyo S.
Ahmed, Kamran A. http://orcid.org/0000-0003-3331-1529
Article History
Received: 23 July 2021
Accepted: 11 October 2021
First Online: 20 October 2021
Declarations
:
: Hsiang-Hsuan Michael Yu has received speaker’s honoraria from BrainLab and is on the advisory boards of Novocure and Abbvie. Michael A. Vogelbaum has indirect equity and royalty rights from Infuseon Therapeutics and has received honoraria from Tocagen, Cellinta, and Celgene. Peter A. Forsyth has received research funding from Pfizer and Celgene and is on the advisory boards of Novocure, BTG, Inovio, Abbvie, Ziopharm, Tocagen, and Pfizer. Hatem Soliman serves as a consultant for AstraZeneca, Celgene, Novartis, PUMA, and Eisai. Brian J Czerniecki has intellectual property on a HER2 dendritic cell vaccine. Hyo S. Han declares that she has received a speaker’s honorarium from Lilly Pharmaceuticals, research funding from Abbvie, Arvinas, GSK, Marker therapeutic, Novartis, Bristol-Myers Squibb, Pfizer, SeattleGenetics, Prescient, Horizon, Zymeworks, and Karyopharm. Kamran A. Ahmed has received research funding from Bristol-Myers Squibb, Eli Lilly, and Genentech.
: This study was approved by the University of South Florida Institutional Review Board.
: Not applicable.
: Not applicable.